Clinical Trial

A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated March 25, 2026 (before its estimated June 7, 2026 completion). Its status may not reflect the trial's current state.
Summary
This multicenter, randomized, double-blind, active-controlled study aims to evaluate the efficacy and safety of picankibart in Chinese patients with plaque psoriasis who demonstrated inadequate responses to interleukin-17 (IL-17) monoclonal antibody therapy and subsequently switched to picankibart. The trial will enroll approximate 310 participants with confirmed plaque psoriasis diagnosis and a poor response to IL-17 monoclonal antibody treatment. The study includes a 4-week screening phase, followed by an active treatment period of either 36 weeks, and concludes with a safety follow-up assessment at Week 48.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-18; most recent amendment 2026-03-24.
Status change: Recruiting → Active, Not Recruiting 2026-03-24
Status change: Not Yet Recruiting → Recruiting 2025-06-11
Trial Details
NCT Number NCT06945107
Lead Sponsor Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions Plaque Psoriasis
Enrollment 308 participants
Start Date 2025-05-27
Primary Completion 2026-06-07 (estimated)
Study Completion 2027-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-03-25